VITAL (machine learning software)

{{Infobox software

| name = VITAL

| logo =

| logo alt =

| logo caption =

| screenshot =

| screenshot size =

| screenshot alt =

| caption =

| collapsible =

| author = Unknown

| developer = Deep Knowledge Venture

| released = no

| discontinued = yes

| ver layout =

| latest release version =

| latest release date =

| latest preview version =

| latest preview date =

| repo =

| programming language = unknown

| engine =

| operating system = unknown

| platform = unknown

| included with =

| size =

| language =

| language count =

| language footnote =

| genre =

| license = unknown

| alexa =

| website =

| standard =

| AsOf =

}}

VITAL (Validating Investment Tool for Advancing Life Sciences) was a Board Management Software machine learning proprietary software developed by Aging Analytics,{{Cite web|title=Deep Knowledge Venture's Appoints Intelligent Investment Analysis Software VITAL as Board Member|url=http://www.globenewswire.com/news-release/2014/05/13/635881/10081467/en/Deep-Knowledge-Venture-s-Appoints-Intelligent-Investment-Analysis-Software-VITAL-as-Board-Member.html|last=Ventures|first=Deep Knowledge|date=2014-05-13|website=GlobeNewswire News Room|access-date=2020-05-06}} a company registered in Bristol (England) and dissolved in 2017. Andrew Garazha (the firm's Senior Analyst) declared that the project aimed "through iterative releases and updates to create a piece of software capable of making autonomous investment decisions." According to Nick Dyer-Witheford, VITAL 1.0 was a "basic algorithm".{{cite book|last=Dyer-Witheford|first=Nick|title=Cyber-proletariat: Global Labour in the Digital Vortex|date=2015|publisher=Pluto Press|isbn=978-0-7453-3404-2|editor1-last=Dean|editor1-first=Jodi|editor-link1=Jodi Dean|location=London|pages=1–2|author-link=Nick Dyer-Witheford|editor2-last=Hands|editor2-first=Joss|editor3-last=Jordan|editor3-first=Tim|editor-link3=Tim Jordan (sociologist)}}

On 13 May 2014, Deep Knowledge Ventures, a Hong Kong venture capital firm, claimed to have appointed VITAL to its board of directors in order to prove that artificial intelligence could be an instrument for investment decision-making.{{Cite web|title=I'm afraid I can't invest in that, Dave: AI appointed to VC funding board - Discovery {{!}} siliconrepublic.com - Ireland's Technology News Service|url=https://www.siliconrepublic.com/discovery/im-afraid-i-cant-invest-in-that-dave-ai-appointed-to-vc-funding-board|last=Gorey|first=Colm|date=2014-05-15|website=Silicon Republic|language=en|access-date=2020-05-06}} The announcement received great press coverage despite the fact commentators consider this a publicity stunt.{{cite news|date=2014-05-16|title=Algorithm appointed board director|publisher=BBC|url=http://www.bbc.com/news/technology-27426942|access-date=2016-01-03|archive-url=https://web.archive.org/web/20160103054816/http://www.bbc.com/news/technology-27426942|url-status=live|archive-date=2016-01-03}} Fortune reported in 2019 that VITAL is no longer used.{{cite news|last=Kahn|first=Jeremy|date=2019-09-26|title=Learning to love the bot: Managers need to understand A.I. logic before using it as a business tool|newspaper=Fortune|url=https://fortune.com/2019/09/26/ai-business-strategy-management/|access-date=2020-04-19|archive-url=https://web.archive.org/web/20200419222011/https://fortune.com/2019/09/26/ai-business-strategy-management/|archive-date=2020-04-19}}

Criticism

Academics and journalists viewed VITAL's board appointment with skepticism. University of Sheffield computer science professor Noel Sharkey called it "a publicity hype". Michael Osborne, a University of Oxford associate professor in machine learning, found it is "a gimmick to call that an actual board member".{{cite news|last=Brown|first=Sophie|date=2014-09-30|title=Could computers take over the boardroom?|publisher=CNN|url=http://www.cnn.com/2014/09/30/business/computers-ceo-boardroom-robot-boss/|access-date=2016-01-03|archive-url=https://web.archive.org/web/20160103054043/http://www.cnn.com/2014/09/30/business/computers-ceo-boardroom-robot-boss/|url-status=live|archive-date=2016-01-03}} Simon Sharwood of The Register, wrote there is "a strong whiff of stunt and/or promotion about this".{{cite news|last=Sharwood|first=Simon|date=2014-05-18|title=Software 'appointed to board' of venture capital firm|newspaper=The Register|url=http://www.theregister.co.uk/2014/05/18/software_appointed_to_board_of_venture_capital_firm/|access-date=2016-01-03|archive-url=https://web.archive.org/web/20160103061058/http://www.theregister.co.uk/2014/05/18/software_appointed_to_board_of_venture_capital_firm/|url-status=live|archive-date=2016-01-03}} In a 2019 speech, the Chief Scientist of Australia, Alan Finkel, commented, "At the time, most of us probably dismissed Vital as a PR exercise. I admit, I used her story three years ago to get a laugh in one of my speeches."{{cite news|last=Finkel|first=Alan|date=2019-03-05|title=The Innovation Imperative|publisher=Office of the Chief Scientist|url=https://www.chiefscientist.gov.au/sites/default/files/AICD-Governance-Summit-2019-Speech-Final.pdf|access-date=2020-04-29|archive-url=https://web.archive.org/web/20200429073607/https://www.chiefscientist.gov.au/sites/default/files/AICD-Governance-Summit-2019-Speech-Final.pdf|archive-date=2020-04-29}}

Florian Möslein, a law professor at the University of Marburg, wrote in 2018 that "Vital has widely been acknowledged as the 'world's first artificial intelligence company director'".{{cite book |last=Mölein |first=Florian |editor1-last=Barfield |editor1-first=Woodrow |editor2-last=Pagallo |editor2-first=Ugo |date=2018 |chapter=Robots in the boardroom: artificial intelligence and corporate law |title=Research Handbook on the Law of Artificial Intelligence |chapter-url=https://books.google.com/books?id=KqV-DwAAQBAJ&pg=PA649 |location=Cheltenham |publisher=Edward Elgar Publishing |pages=649–650 |isbn=978-1-78643-904-8 |access-date=2020-04-19 }} Vice journalist Jason Koebler suggested that the software did not have any article intelligence capabilities and concluded "VITAL can’t talk, and it can’t hear, and it can’t be a real, functional executive of a company."{{cite news|last=Koebler|first=Jason|date=2014-05-13|title=The First Robot Venture Capitalist Won't Do Interviews|newspaper=Vice|url=https://www.vice.com/en/article/the-robot-turned-venture-capitalist-exec-isnt-giving-interviews/|access-date=2016-01-03|archive-url=https://web.archive.org/web/20160103055647/http://motherboard.vice.com/read/the-robot-turned-venture-capitalist-exec-isnt-giving-interviews|url-status=live|archive-date=2016-01-03}} Sharwood of The Register noted that because VITAL was not a natural person, it could not be a board member under Hong Kong's corporate governance laws. However, in a 2017 interview to The Nikkei, Dmitry Kaminskiy, managing partner of Deep Knowledge Ventures, stated that VITAL had observer status on the board and no voting rights.{{cite news|last=Burridge|first=Nicky|date=2017-05-10|title=Artificial intelligence gets a seat in the boardroom: Hong Kong venture capitalist sees AI running Asian companies within 5 years|newspaper=The Nikkei|url=https://asia.nikkei.com/Business/Artificial-intelligence-gets-a-seat-in-the-boardroom|access-date=2020-04-19|archive-url=https://web.archive.org/web/20200419222157/https://asia.nikkei.com/Business/Artificial-intelligence-gets-a-seat-in-the-boardroom|archive-date=2020-04-19}}

University of Sheffield computer science professor Noel Sharkey said of VITAL, "On first sight, it looks like a futuristic idea but on reflection it is really a little bit of publicity hype." Vice journalist Jason Koebler said "this is a gimmick" and said "There is literally nothing to suggest that VITAL has any sort of capabilities beyond any other proprietary analysis software". Michael Osborne, a University of Oxford associate professor in machine learning, found VITAL's appointment to be noncredible, saying it is "a bit of a gimmick to call that an actual board member". Osborne said that a core duty of board members to converse with each other, which the algorithm is incapable of doing, so its more likely functionality is to serve as a springboard for conversation among other board members. In a 2019 speech, the Chief Scientist of Australia, Alan Finkel, commented, "At the time, most of us probably dismissed Vital as a PR exercise. I admit, I used her story three years ago to get a laugh in one of my speeches."

Machine intelligence as board member

VITAL was created by a group of programmers employed by Aging Analytics {{Cite web|title=Aging Analytics UK Launches VITAL, a Predictive Investment Tool For the Regenerative Medicine Sector', 13 May|url=https://www.thecorporatecounsel.net/nonMember/docs/05_14_AgingAnalytics.pdf|last=Fontaine|first=Jessica|date=2014|website=Cadogan Consulting Group|access-date=6 May 2020}} According to Andrew Garazh, Aging Analytics Senior Analyst, VITAL was not a machine learning algorithm as the necessary datasets on investment rounds, intellectual property and clinical trial outcomes are generally not disclosed. Rather, VITAL used fuzzy logic based on 50 parameters to assess risk factors.

Aging Analytics licensed the software to Deep Knowledge Ventures.{{cite journal|last=Lin|first=Shaowei|date=2018|title=人工智能对公司法的影响:挑战与应对|trans-title=The impact of artificial intelligence on company law: challenges and responses|url=http://www.civillaw.com.cn/uploadfile/lmpic/20180619/20180619064349418.pdf|journal=Journal of East China University of Political Science and Law|language=zh|publisher=East China University of Political Science and Law|access-date=2020-04-19|via=CNKI}} It was used to help the human board members of Deep Knowledge Venture make investment decisions in biotechnology companies. For instance, it supported investments in Insilico Medicine,{{Cite web|title=Deep Knowledge Ventures and Insilico Medicine Enter into a Convertible Bridge Note Agreement to Combat Aging|url=https://www.businesswire.com/news/home/20150211006103/en/Deep-Knowledge-Ventures-Insilico-Medicine-Enter-Convertible|date=2015-02-11|website=www.businesswire.com|language=en|access-date=2020-05-06}} which creates ways for computers to help find drugs in research into aging. VITAL also supported investing in Pathway Pharmaceuticals,{{Cite web|title=Deep Knowledge Ventures announces new investment fund for life sciences and aging research|url=http://www.eurekalert.org/pub_releases/2015-12/brf-dkv121515.php|website=EurekAlert!|language=en|access-date=2020-05-06}} which uses the OncoFinder algorithm{{Cite journal|last1=Buzdin|first1=Anton A.|last2=Zhavoronkov|first2=Alex A.|last3=Korzinkin|first3=Mikhail B.|last4=Roumiantsev|first4=Sergey A.|last5=Aliper|first5=Alexander M.|last6=Venkova|first6=Larisa S.|last7=Smirnov|first7=Philip Y.|last8=Borisov|first8=Nikolay M.|date=2014-08-26|title=The OncoFinder algorithm for minimizing the errors introduced by the high-throughput methods of transcriptome analysis|journal=Frontiers in Molecular Biosciences|volume=1|pages=8|doi=10.3389/fmolb.2014.00008|issn=2296-889X|pmc=4428387|pmid=25988149|doi-access=free }} to choose and appraise cancer treatments. According to Dmitry Kaminskiy, managing partner of Deep Knowledge Ventures, the motivation for using VITAL was the large number of failed investments in the biotechnology sector and the desire to avoid investing in companies likely to fail.

References